Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O60285
UPID:
NUAK1_HUMAN
Alternative names:
AMPK-related protein kinase 5; Omphalocele kinase 1
Alternative UPACC:
O60285; A7MD39; Q96KA8
Background:
NUAK family SNF1-like kinase 1, also known as AMPK-related protein kinase 5 and Omphalocele kinase 1, plays a pivotal role in cell adhesion, regulation of cell ploidy and senescence, cell proliferation, and tumor progression. It phosphorylates key proteins such as ATM, CASP6, LATS1, PPP1R12A, and p53/TP53, influencing cellular senescence, DNA damage response, and tumor malignancy.
Therapeutic significance:
Understanding the role of NUAK family SNF1-like kinase 1 could open doors to potential therapeutic strategies.